Bausch Health Reports Second Quarter 2024 Fiscal Performance

Bausch Health Companies Inc. revealed its financial results for the second quarter of 2024, highlighting notable growth. The company’s consolidated revenues reached $2.40 billion, a rise of 11% compared to the previous year. Organic growth stood at 8%, factoring out acquisitions, divestitures, and foreign exchange impacts.

The consolidated net income stood at $10 million. Meanwhile, the adjusted EBITDA climbed to $798 million, marking a 10% increase. This growth marks the fifth consecutive quarter of year-over-year gains in both revenue and adjusted EBITDA.

The company’s Bausch + Lomb segment significantly contributed to this growth, with revenues up by 17% year-over-year, reaching $1.216 billion. Other segments also reported positive performances, notably the Solta Medical segment, which grew by 16%, led by strong results in Asia-Pacific.

Bausch Health has raised its full-year 2024 guidance for both revenue and adjusted EBITDA, reflecting the company’s optimistic outlook for continued performance improvements across its various business segments.